- How to Limit The Health Risks Posed by Polluted Air
- U.S. States Warm, But Not As Expected
- Rovner Recaps Medicaid Cuts’ Impact on Hospitals and Fields Caller Questions on Affordability
- CMS proposes mandatory hospital-bundled model for joint replacements
- CMS proposes mandatory hospital-bundled model for joint replacements
- CMS pitches 2.4% hospital pay bump, mandatory joint replacement model: 7 things to know
- Mayo Clinic enhances imaging test with AI
- Christus Health to open Texas multi-specialty clinic
- CMS proposes extension of prior authorization rule to cover drugs: 6 notes
- Penn Medicine, Epic lean into EHR ‘nudges’
- AdventHealth breaks ground on $27M freestanding ER
- Henry Ford hospital strike enters 7th month: 6 notes
- Texas launches rural hospital leadership academy
- Children’s Minnesota staff email account compromised
- UHS’ CEO-to-worker pay ratio over the past 5 years
- Medicaid’s consistency problem in dentistry
- Dental groups seek $600M+ in FY 2027 federal budget: 5 notes
- Missouri dental school grows student body by 33% to combat dentist shortages
- Prior authorization by the numbers: 10 stats that show the strain
- The Trump Administration Is Seeking Federal Workers’ Sensitive Medical Data. That’s Raising Alarms.
- 5 new university programs tackling behavioral health workforce gaps
- Texas Children’s gets $5M gift for behavioral health services
- Cardiology malpractice cases by the numbers
- Texas Children’s receives $5M estate gift for behavioral health
- CMS proposes 2.4% hospital pay increase, nationwide mandatory model rollout
- Which physician specialty is most likely to have a salaried paycheck?
- 20+ dental education updates to know from Q1
- Proposed CMS rule would set prior auth deadlines for drugs
- The best orthopedic ASCs in the West: US News
- 4 clinics closing after physician owner sentenced for selling recalled medical devices as new
- VA program deploys 700+ VR ‘mental wellness’ kits
- The cost of private equity firms owning residential SUD facilities: 4 things to know
- 10 highest, lowest-paying physician specialties
- Independent GI practices shrinks as reimbursements fall 38% over a decade
- HHS, after legal setback, updates ACIP charter to put more emphasis on vaccine safety
- HHS, after legal setback, updates ACIP charter to put more emphasis on vaccine safety
- New York system to open $12M outpatient imaging center
- Costco Recalls Cookies Over Missing Nut Allergy Warning
- CDC Pauses Release of COVID Vaccine Effectiveness Study
- Pharma company withdraws FDA application amid White House autism treatment push
- Endoscopy at scale: The reprocessing best practices separating high-performing teams
- Demand Surge Leads to Shortages of Estrogen Patches
- What to know about the fastest-growing DSO
- 4 DSOs making headlines
- Statement Regarding Staff No-Action Letter to Bank of England
- Op-ed: Administrative fragility is costing healthcare more than we think
- Alaska city opens addiction treatment microunit program
- Title X Funding Restored, but New Rules Raise Concerns
- Function Health acquires mobile healthcare platform Getlabs to provide members with at-home lab tests
- The Healthcare Burnout Backlash (pt 3): How Workflow Redesign Is Helping Healthcare Organizations Offset Staffing Shortages
- The Healthcare Burnout Backlash (pt 3): How Workflow Redesign Is Helping Healthcare Organizations Offset Staffing Shortages
- BD Announced Application of CE Mark for the Liverty TIPS Stent Graft
- BD Announced Application of CE Mark for the Liverty TIPS Stent Graft
- Blackstone and TPG Complete Acquisition of Hologic; Names New CEO
- Blackstone and TPG Complete Acquisition of Hologic; Names New CEO
- Endospan Receives FDA Approval for the NEXUS Aortic Arch Stent Graft System
- Endospan Receives FDA Approval for the NEXUS Aortic Arch Stent Graft System
- InVera Medical Receives FDA Clearance for Non-Thermal Chronic Venous Disease Device
- InVera Medical Receives FDA Clearance for Non-Thermal Chronic Venous Disease Device
- Starting material sourcing bottlenecks increase US drug shortage risks: report
- Novartis cuts 114 more jobs at New Jersey HQ as restructuring rolls on
- Charles River flows into Boston to help AHA bridge cardiovascular health divide
- Your Brain Cares If Your Plant-Based Diet Is Unhealthy, Researchers Report
- Your Neighborhood Might Help Make You Old Before Your Time
- Heavy 'Forever Chemical' Exposure Before Birth Increases Childhood Asthma Risk, Study Finds
- High-Tech Magnets Offer New Hope for Veterans Battling Combat PTSD
- Early Diagnosis Key To ADHD Child's Academic Success, Study Finds
- Study Reveals Who Americans Think Should Pay for Elder Care
- Envision hires ConcertAI, IQVIA alum Nick Jones as its med comms president
- The top 10 pharma R&D budgets of 2025
- For Many Patients Leaving the ICU, the Struggle Has Only Just Begun
- Watch: As AI Makes More Health Coverage Decisions, the Risks to Patients Grow
- Bial launches ‘Dialogues with Parkinson’s’ campaign aimed at identifying early symptoms
- Novartis pumps up community health footprint to tackle heart disease and cancer
- Abbott survey finds ‘information overload, confusion and cost’ affecting health choices in US
- FDA accuses Amneal, BioCorRx of producing ‘false and misleading’ drug promos
- North Carolina provider launches mobile opioid treatment unit
- U of Pittsburgh debuts online infant mental health certificate
- Emerging DSO lands Ohio partnership
- Heartland Dental added 5 de novos in March
- The states with the highest, lowest migration rate of dentists since 2019
- What the Health? From KFF Health News: Abortion Pills, the Budget, and RFK Jr.
- Specialty DSO eyes new growth levers after entering several states
- Hospital M&A roars back to life in Q1 2026; Operating performances fray in February
- Epic rolls out health alerts to flag rising rates of illness at the county level
- Fierce Pharma Asia—Takeda-Denali split-up; Merck, Zhifei's revised deal; Shionogi's made-in-US plan
- Brain Scans Reveal How Psychedelics Change Perception
- Benefits leaders report increased operational, financial costs amid 'digital health vendor sprawl': Solera survey
- Vanda initiates study of motion sickness drug Nereus in GLP-1 users
- Judge Allows Abortion Pill, Mifepristone, To Continue Being Mailed for Now
- Bangladesh Measles Outbreak Kills 100+ Kids, Emergency Shots Begin
- Regulatory burdens continue to mount for physician practices
- Medicare navigation company Chapter banks $100M series E funding round
- Hair Growth Product, Tuymec Minoxidil Hair Growth Kits, Recalled Over Child Poisoning Risk
- Garda snaps up Assertio and chemo infection treatment Rolvedon in $125M deal
- AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit
- AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit
- Eli Lilly launches oral GLP-1 drug across US through Lilly Direct, telehealth providers
- Humana, Noom and Welldoc team up with b.well to expand health data access as part of CMS push
- America's Sexual Health Report Card Contains Some Surprises
- Years of Excess Weight, Not One Bad Checkup, Drive Heart Disease Risk
- There Are No Good Ways To Avoid Childhood Eczema But Many Treatment Options
- More Children, Teens At Risk From E-Scooter Crashes, Study Finds
- This Treatment Can Improve Your Odds Of Surviving C. Diff Infection
- Alzheimer’s Tests May Mask Risks for Women
- RFK Jr. launching health podcast to expose ‘hypocrisy’ and ‘corruption’
- RFK Jr. launching health podcast to expose ‘hypocrisy’ and ‘corruption’
- Advocate Health improves to 4% operating margin, $4.6B bottom line across 2025
- Farm Bureau Health Plans Beat the ACA on Prices With an Age-Old Tactic: Rejecting Sick People
- States Face Another Challenge With Medicaid Work Rules: Staffing Shortages
- Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs
- Judge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffs
- Judge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffs
- Consumers' satisfaction with health plan apps improves with familiarity: JD Power
- Nurses' job satisfaction stumbles after post-pandemic gains: survey
- Amazon launches 2 new digital health partnerships for nutrition therapy, sleep care in health conditions program
- Former NFL Star Steve McMichael Diagnosed With CTE After His Death
- Steven Ubl set to depart after more than a decade as CEO of PhRMA
- Nixing prior auth, outlier hospital bills could lower health costs, Center for American Progress' policy plan says
- Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant
- More Drugmakers Join TrumpRx
- Graco Recalls Infant Car Seats Over Structural Issue
- Orlando Health fleshes out Alabama footprint with another acquisition
- US adults still turn to providers for accurate health information even as AI chatbot use grows: Pew survey
- Pfizer walks away from 'underutilized' office space in South San Francisco, transitions employees to remote roles
- Biogen settles investor lawsuit over its messaging on failed Alzheimer's drug Aduhelm
- Digital health startups raked in $4B during Q1 with 12 megadeals driving investment: Rock Health
- New Cervix-On-A-Chip May Revolutionize STI Treatment
- The Flu Vaccine Can Lower Your Risk Of Heart Attack And Stroke — Even If You Wind Up Infected
- Long COVID Linked to Heart Health Risks
- Herbal Drug Kava Poses Increasing Health Threat In U.S., CDC Warns
- Preschoolers' Solitary Screen Time Could Mean Behavior Problems, Language Difficulties Later On
- Combo Heat Waves/Droughts Will Affect Billions A Year By 2100, Researchers Project
- Amgen CEO netted $24.7M pay package in ‘25 as company’s upward trajectory continued
- J&J's Tremfya retakes TV drug ad spending crown from AbbVie
- Urgent Care Clinics Move To Fill Abortion Care Gaps in Rural Areas
- Trump’s Personnel Agency Is Asking for Federal Workers’ Medical Records
- FDA Approves First Generic Farxiga (dapagliflozin) Tablets
- Reliance on EHR vendors' tech roadmap slows down AI progress, senior IT leaders say
- ¿Puedo decirle a mi médico que no quiero que use la inteligencia artificial para tomar notas?
- Remarks at the Texas Stock Exchange Event: Welcome to the Boom Belt: A Return to First Principles in Public Markets
- Wawa Recalls Drinks Over Undeclared Milk Allergen
- Scientists Test New Ways To Regrow Joints Damaged by Arthritis
- This New Method May Make French Fries Lower in Fat
- U.S. Plans Tariffs up to 100% on Some Brand-Name Drugs
- Americans May Be Losing Trust for AI in Health Care: Survey
- Cheap Blood Test Might Spot Cancers, Other Diseases
- Danger at Home: Cleaning Products Are Harming Kids
- Could a High-Dose Flu Shot Lower Your Alzheimer's Risk?
- Allevion Medical Receives 510K Clearance for Vantage Spinal Decompression System
Costco does not break out their pharmacy sales from their quarter trillion dollar overall sales, but their 614 U.S. warehouses are a major player in pharmaceutical sales:
Costco Says It Will Not Sell Abortion Pill Mifepristone
The company attributes its decision to lack of demand.
By Aldgra Fredly - August 15, 2025Costco Wholesale said on Aug.14 that it would maintain its stance of not selling the abortion pill mifepristone at its U.S. pharmacies due to low customer demand.
Mifepristone is a drug that blocks progesterone, the hormone needed for sustaining pregnancy. The Food and Drug Administration (FDA) approved the drug in 2000 for terminating pregnancy through 10 weeks of gestation, stating on its website that mifepristone is safe when used properly.
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the retailer said in a statement to multiple news outlets.
The move comes amid campaigns against the pill from faith-based groups, including exchange-traded fund provider Inspire Investing and legal advocacy group Alliance Defending Freedom (ADF).
ADF legal counsel Michael Ross applauded Costco for its decision.
“Retailers like Costco keep their doors open by selling a lifetime of purchases to families, both large and small. They have nothing to gain and much to lose by becoming abortion dispensaries,” Ross said in a statement.
Students for Life America (SFLA) praised the move as “a stunning win for life,” saying that it hopes more companies would follow Costco’s policy.
“Costco Wholesale insists its reason was not based on pressure from groups like ours,” SFLA stated. “We at PLG [pro-life generation] never expected an acknowledgement or public change of corporate heart on record. But we would still like to commend the pro-life movement for speaking sense into Costco Wholesale, resulting in saving the lives of the preborn and women.”
In May, Health Secretary Robert F. Kennedy Jr. ordered the FDA to review mifepristone after an analysis found that nearly 11 percent of women who took the drug experienced serious adverse events, including sepsis and hemorrhaging.
That percentage is higher than the summary figure of less than 0.5 percent in clinical trials reported on the drug label, according to the Ethics and Public Policy Center, which published the analysis.
“I think the new data … is alarming, and clearly it indicates that at the very least, the label should be changed,” Kennedy said on May 14.
In July 2024, New York City Comptroller Brad Lander sent letters to Costco and other retailers to dispense the abortion drug in states where it is legal. In his letter to Costco, Lander warned that failing to do so could raise “significant investor concerns,” noting that the New York City Retirement Systems held $443.9 million in Costco stock.
Several investment advisers and corporate engagement consultants representing investors who held $56 million in Costco stock sent a letter to the retailer urging it not to sell mifepristone.
Their petition received support from thousands of investors and customers.
Costco got lit up by one of their home state Senators for their decision not to sell mifepristone:
https://thehill.com/policy/healthcare/5455913-patty-murray-costco-abortion-pill-mifepristone/
Senate Democrat rips Costco for ‘refusing to sell’ abortion pills
By Steff Danielle Thomas - August 16, 2025Sen. Patty Murray (D-Wash.) hammered Costco on Friday for appeasing “far-right extremists,” after the retailer said earlier this week that its pharmacies would not dispense the abortion medication mifepristone.
“I am deeply alarmed by news reports that Costco is refusing to sell safe, effective, and legal medication for no other reason than to appease the politics of anti-abortion fanatics,” Murray said in a statement following the news. “I refuse to stand by and allow far-right extremists to bully major corporations and dictate what medicine women can or cannot get access to.”
“Where it is legal, retailers and major pharmacies must absolutely make medication abortion available to the women who need it,” the Washington Democrat added.
Costco, in its Thursday announcement, explained that the decision came from a “lack of demand.”
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the company said, according to Reuters.
The decision comes after CVS and Walgreens announced last year that they received certification to provide the drug in states where abortion remains legal.
Murray pressed Costco to rescind its decision, warning that limiting access to mifepristone, one of two drugs used in medication abortion, is harmful to women’s health.
“Mifepristone is safe and effective—we cannot live in a world where the availability of women’s health care whipsaws back and forth based on the whims of extremists who want to deny women access to basic health care,” she wrote Friday. “I am demanding that Costco immediately reverse course—follow the science and the facts, not the demands of far-right anti-abortion extremists.”
The Supreme Court in a decision last year ruled unanimously that a group of anti-abortion doctors did not have the legal basis to challenge access to the pill.
Despite the ruling, Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary are weighing a review of the abortion pill.
Murray questioned Makary during his Senate confirmation hearing on the proposal, as well as President Trump’s moves to gut staff at the FDA.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.



















